Viatris Inc logo

Viatris Inc

€ 8.78 (-2.26%) Sep 29
P/E:
13.50
P/B:
0.52
Market Cap:
€ 10.74B ($ 10.53B)
Enterprise V:
€ 31.68B ($ 31.06B)
Volume:
-
Avg Vol (2M):
558.00
Also Trade In:
Volume:
-
Market Cap €:
10.74B
Market Cap $:
10.53B
PE Ratio:
13.50
Avg Vol (2-Month):
558.00
Enterprise Value €:
31.68B
Enterprise Value $:
31.06B
PB Ratio:
0.52
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Financials (Next Earnings Date:2022-11-08 Est.)

WBO:MYL's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 15,398.982
EPS (TTM) (€) 0.572
Beta 0.49
Volatility % 31.18
14-Day RSI 34.68
14-Day ATR (€) 0.182987
20-Day SMA (€) 9.36595
12-1 Month Momentum % -18
52-Week Range (€) 8.78 - 13.526
Shares Outstanding (Mil) 1,212.58

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Viatris Inc Filings

Document Form Filing Date
No Filing Data

Viatris Inc Analysis

Share your research